Semaglutide reduces COVID-19 related deaths in patients with obesity and cardiovascular disease
Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease (CVD) without diabetes, according ...
Aug 30, 2024
0
1